Wave Life Sciences (WVE) Emerges as Obesity Treatment Contender, Oppenheimer Boosts Price Target [Yahoo! Finance]
Wave Life Sciences Ltd. - Ordinary Shares (WVE)
Last wave life sciences ltd. - ordinary shares earnings: 3/2 06:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.wavelifesciences.com/news-releases?page=1%2c0%2c0%2c0
Company Research
Source: Yahoo! Finance
Wave Life Sciences Ltd. (NASDAQ:WVE) to $32 from $24, maintaining an Outperform rating on the company's shares. The firm reported “highly encouraging” interim results for WVE-007, emphasizing the treatment's clean risk profile at doses up to 600mg and apparent ease of translation from human genetics and preclinical research to clinical outcomes. According to Wave Life Sciences Ltd. (NASDAQ:WVE), the medication, when taken for three months, resulted in a 4.5% total fat loss, a 9.4% visceral fat reduction, and a 3.2% gain in lean mass. Wave Life Sciences Ltd (NASDAQ:WVE) stated it plans to release the results of the second round of the clinical trial, which will span six months for the 240 mg single-dose cohort and three months for the 400 mg single-dose cohort. Beyond its immediate applications, Oppenheimer sees WVE-007 as a possible core therapy for not only obesity but also other cardiometabolic diseases. Wave Life Sciences Ltd. (NASDAQ:WVE) is a clinical-stage biotech company
Show less
Read more
Impact Snapshot
Event Time:
WVE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
WVE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
WVE alerts
High impacting Wave Life Sciences Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
WVE
News
- Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio [Yahoo! Finance]Yahoo! Finance
- Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing PortfolioGlobeNewswire
- WAVE Life Sciences (NASDAQ:WVE) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=WVE&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street ZMarketBeat
- Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- WAVE Life Sciences (NASDAQ:WVE) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=WVE&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreetMarketBeat
WVE
Earnings
- 11/10/25 - Miss
WVE
Sec Filings
- 1/12/26 - Form 8-K
- 1/6/26 - Form 4
- 12/15/25 - Form SCHEDULE
- WVE's page on the SEC website